Selank: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Selank is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

Selank comes from the same Russian research lineage as Semax, shares its stabilizing engineering trick, and is almost always discussed in the same breath — but it does something close to the opposite job in the brain, and, as of 2026, it’s ended up in a genuinely different regulatory position too. Both of those distinctions are worth understanding clearly before treating the two as interchangeable siblings.

Quick Facts

Class	Synthetic tuftsin analog
Structure	Tuftsin-derived heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with a Pro-Gly-Pro stabilizing tail
Primary research use	Anxiety reduction, stress resilience, mood stabilization
Administration	Subcutaneous or intranasal
Typical effective range (community-reported)	500mcg once daily
Evidence tier	Genuine, completed Phase III trial in Russia; evidence quality doesn’t meet Western regulatory standards
Regulatory status	Approved in Russia since the early 2000s; not approved in the US, Canada, or EU

The Story So Far

Selank was developed by the same research group behind Semax — the Institute of Molecular Genetics of the Russian Academy of Sciences — but built from a different starting point. Rather than a fragment of ACTH, Selank is derived from tuftsin, a naturally occurring immunoregulatory tetrapeptide. Researchers extended it with the same Pro-Gly-Pro stabilizing tail used in Semax’s design, a shared engineering signature between the two compounds even though their underlying biology and effects diverge sharply from there.

Selank has been approved for clinical use in Russia since the early 2000s, primarily as a prescription intranasal formulation for generalized anxiety disorder and neurasthenia (a diagnosis roughly corresponding to chronic fatigue with mood and cognitive symptoms). It’s genuinely completed Phase III clinical trials in Russia for generalized anxiety disorder — a real, late-stage clinical development program, not just early exploratory work. One frequently cited comparative study, involving 62 patients with GAD, found Selank produced anxiolytic efficacy similar to a benzodiazepine comparator, with the added observation that Selank carried anti-fatigue effects the benzodiazepine didn’t. Worth being upfront about a limitation here: full study details are difficult to obtain in English, since only the abstract has been indexed in Western databases like PubMed — a specific, recurring problem with evaluating this body of research from outside Russia.

Here’s where Selank’s story genuinely diverges from Semax’s, despite their shared origin. As of 2026, Semax was removed from FDA Category 2 restrictions in April, as part of a broader reclassification, and is specifically scheduled for a Pharmacy Compounding Advisory Committee review in July 2026 — an active, ongoing regulatory process. Selank’s path was different: it was removed from Category 2 back in September 2024, but for a different reason entirely — the original party who had nominated it for that restricted category withdrew the nomination altogether, which removed Selank from the compounding framework rather than advancing it toward a decision. Without an active nomination, there’s currently nothing for the FDA’s advisory committee to review, and no clear pathway for Selank to move toward a different classification unless someone re-nominates it and the evaluation process restarts. This is US-specific regulatory detail with no direct bearing on the Canadian legal picture, but it’s worth knowing if you encounter claims online that treat Semax and Selank as having identical current status — they don’t.

What It Actually Does

Selank’s primary, best-characterized mechanism is modulating the GABAergic system — the brain’s main inhibitory, calming neurotransmitter pathway. A 2018 radioligand binding study found that Selank enhances GABA binding at the GABA-A receptor without engaging the same binding site benzodiazepines use. That’s a meaningful mechanistic distinction, not a technicality: it’s the basis for Selank’s reputation as producing calming, anxiolytic effects without the sedation, cognitive impairment, or dependency risk associated with drugs that work through the classical benzodiazepine binding site.

Beyond GABAergic modulation, Selank influences serotonin signaling, contributing to its mood-stabilizing profile, and has shown BDNF-related effects in animal research — a 2019 study found it protected against ethanol-induced memory impairment in rats by regulating BDNF content in the hippocampus and prefrontal cortex, giving it a secondary mechanistic overlap with Semax’s neuroprotective profile despite their otherwise different primary actions.

What the Research Shows

As with Semax, Selank’s evidence picture is genuinely substantial in one sense and genuinely limited by Western standards in another — both things are true at once.

The Russian clinical trial history is real and reasonably advanced. A completed Phase III program for generalized anxiety disorder is a real, late-stage clinical achievement — most compounds in this guide series haven’t gotten anywhere close to that stage of development. The 62-patient benzodiazepine-comparison study is a genuinely interesting, if incompletely documented, data point suggesting comparable efficacy to an established anxiolytic class, with a potentially favorable difference in fatigue.

Access to the full underlying data is a real, practical limitation. Much of this research exists only in Russian-language publications or as English abstracts without full accompanying data — a recurring problem for evaluating Russian-origin peptide research generally, and one that limits how thoroughly outside researchers can assess study design, blinding, and statistical rigor.

Animal research provides converging mechanistic support. Rodent studies have found improved maze navigation and memory retention, reduced anxiety-like behavior under stress, and the BDNF-related protective effects described above — consistent with, though not a substitute for, the human clinical trial history.

The honest summary mirrors Semax’s: real, sustained clinical development and use in Russia, evidence quality that doesn’t meet the trial-design standards Western regulators require, and no completed Western randomized controlled trial to independently corroborate the Russian findings.

How It Compares

Selank sits alongside Semax in the cognitive category — the two most-studied peptides to emerge from Russian nootropic and neurological pharmacology, sharing an origin lab and a stabilizing structural motif, while doing nearly opposite jobs.

	Selank	Semax
Primary effect	Calming — anxiolytic, mood-stabilizing	Activating — cognitive engagement, alertness
Core mechanism	GABA-A positive allosteric modulation, serotonergic effects	BDNF upregulation, monoamine modulation
Russian approval basis	Completed Phase III trials, GAD	Approved 1994, cerebrovascular and cognitive indications
Current FDA compounding path (US-specific; not applicable in Canada)	No active nomination as of this writing; no clear path to Category 1 without re-nomination	Actively under PCAC review, scheduled July 2026
Best paired for	Reducing anxiety that could otherwise undercut focus	Cognitive engagement and clarity

The two are frequently combined precisely because they’re mechanistically distinct rather than redundant — more on that below.

Who Shouldn’t Use This

Selank has no FDA or Health Canada approval, so there’s no official North American contraindications list. Based on the available literature:

• Concurrent use of prescription anxiolytic or antidepressant medication. Given Selank’s serotonergic and GABAergic activity, there’s real potential for pharmacological interaction with SSRIs, benzodiazepines, or similar medications. This is a genuine reason to seek medical guidance before combining Selank with an existing prescription, not a generic caution.
• Pregnancy or breastfeeding. No adequate safety data exists in this context.

Beyond these, no established absolute contraindications exist in the available literature — reflecting, as with Semax, a body of evidence that’s substantial in duration but doesn’t meet Western trial-design standards for a comprehensive safety picture.

Common Myths, Addressed

“Selank and Semax have the same current legal status since they came from the same lab.” Not accurately, as of 2026. Semax is under active FDA review toward a possible compounding pathway; Selank’s nomination was withdrawn, leaving it without a current path forward absent a new nomination. Shared origin doesn’t mean shared regulatory trajectory.

“GABA-A modulation means this works just like a benzodiazepine, including the dependency risk.” The mechanism specifically avoids the benzodiazepine binding site, which is the basis for Selank’s reported lack of sedation and dependency in Russian clinical use and community reporting. This is a real, meaningful distinction, not just favorable framing.

“Since it’s completed Phase III trials, it meets the same evidence bar as an FDA-approved anxiolytic.” A real, genuine late-stage trial program — but conducted under Russian regulatory standards, with much of the underlying data difficult to access and independently evaluate from outside Russia. That’s a different claim than meeting FDA or Health Canada’s evidentiary bar.

What Researchers Are Actually Experiencing

Selank’s calming profile makes its timing considerably more flexible than Semax’s in community discussion — morning use for daytime anxiety support, evening use for sleep-focused objectives, without the sleep-disruption concern that limits Semax to morning administration for most researchers.

Most researchers report settling around 500mcg once daily, often starting at 250–300mcg for the first week or two before deciding whether to increase — many find they don’t need to. Mild sedation at higher doses is reported somewhat more often than with Semax, consistent with Selank’s calming mechanism, though this is generally described as mild and dose-dependent rather than a significant impairment.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Route	Typical Dose	Frequency
Standard	500mcg	Once daily
Starting point	250–300mcg	Once daily, first 1–2 weeks
Intranasal	250–500mcg	Once daily, divided across nostrils

Run for 4 weeks, then take 4 weeks off — this cycling pattern is the community standard, balancing consistent use against indefinite continuous dosing.

Worked Dose Math

At 5mg/mL (a 10mg vial — standard 3mL vial capacity — reconstituted with 2mL BAC water):

• 250mcg (0.25mg) → 0.05mL → 5 units
• 300mcg (0.3mg) → 0.06mL → 6 units
• 500mcg (0.5mg) → 0.1mL → 10 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe. Research ranges here are in micrograms — convert to milligrams before applying the formula.

Vial Planning

A 10mg vial at 5mg/mL gives you 10mg total. At a steady 500mcg/day, that’s 20 days per vial — comfortably covering a standard 4-week on-cycle with some margin.

Reconstitution and Storage — The Short Version

Selank reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days. For the complete process, see our dedicated reconstitution and storage guide. As with Semax, intranasal preparation typically uses a different concentration and format than the subcutaneous approach described above.

Sourcing

Nothing Selank-specific beyond the general picture — see our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Once daily, subcutaneous or intranasal. No fasting required. Timing is flexible — morning for daytime anxiety support, evening for sleep-focused use.

Best Practices

• Start at the lower end (250–300mcg) for the first week or two, even though many researchers find they don’t need to increase beyond it.
• Build the 4-weeks-on, 4-weeks-off cycle into your protocol from the start, rather than treating continuous use as the default.
• If you’re on a prescription SSRI, benzodiazepine, or similar medication, talk to a healthcare provider before combining it with Selank — this is a genuine interaction consideration, not boilerplate caution.
• Track your protocol from day one — dose, route, timing, and observed effects, at minimum.

Common Mistakes to Avoid

• Assuming Selank and Semax share identical current legal status because they share an origin lab — their 2026 regulatory paths have actually diverged.
• Combining with prescription anxiolytics or antidepressants without medical guidance, given the real potential for serotonergic or GABAergic interaction.
• Not recording the reconstitution volume, turning every dose calculation into a guess.
• Skipping the cycling schedule and running continuously by default, rather than treating the 4-weeks-on/4-weeks-off pattern as standard practice.

What Happens If You Stop

There’s no dedicated discontinuation research specific to this question, but this is one of Selank’s more genuinely reassuring points: no dependency or withdrawal effects have been reported in Russian clinical use or community research, which is precisely the safety advantage its avoidance of the benzodiazepine binding site is understood to provide. The standard 4-week cycling pattern already builds planned discontinuation into typical use, rather than treating continuous use as the default.

What to Expect, Week by Week

• Days 1–7: Calming effects, where present, are often reported within the first several days.
• Weeks 1–2: Most researchers use this window to decide whether 250–300mcg is sufficient or whether to move to the standard 500mcg dose.
• Weeks 3–4: The end of a standard cycle, followed by the community-standard 4-week break before resuming.

Individual timelines vary substantially, and this pattern comes primarily from community report rather than trial data specific to this research use case.

Combining With Other Compounds

Selank’s most common pairing is Semax, for the same “calm focus” combination described in our Semax guide — Selank’s anxiety reduction and emotional steadiness alongside Semax’s cognitive engagement and alertness. The rationale is complementary: Semax alone can feel overstimulating for some researchers, and Selank alone may feel insufficiently activating for a cognitive-performance objective. A common community approach is Semax in the morning, with Selank administered either simultaneously or later in the day as needed.

Common Questions

Is Selank actually a real, approved drug somewhere? Yes — it’s been approved in Russia since the early 2000s for generalized anxiety disorder and neurasthenia, based on a completed Phase III clinical trial program. It has no equivalent approval in Canada, the US, or the EU.

Can I get this legally in Canada? See our Canadian regulatory guide for the framework that actually applies here. The US situation is different and not transferable: unlike Semax, Selank currently has no active FDA nomination or review process at all, following a 2024 nomination withdrawal — but that’s a US-specific detail with no direct bearing on Canadian legal status.

Does Selank carry the same dependency risk as a benzodiazepine? No documented dependency or withdrawal has been reported in Russian clinical use or community research, consistent with its mechanism specifically avoiding the benzodiazepine binding site on the GABA-A receptor.

Why is Selank almost always discussed alongside Semax? Shared origin lab, shared stabilizing structural design, and a genuinely complementary effect profile — one calming, one activating — that many researchers find useful together for sustained, non-anxious cognitive performance.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Confirmed you’re not currently on a prescription anxiolytic or antidepressant, or sought medical guidance if you are
• [ ] Decided on a route (subcutaneous or intranasal) based on your specific priority
• [ ] Planned your 4-weeks-on, 4-weeks-off cycle before starting
• [ ] Have a tracking method ready for dose, route, and observed effects
• [ ] Understand the evidence base is substantial in duration but doesn’t meet Western trial-design standards

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Route	Dose	Frequency
Starting point	250–300mcg	Once daily, first 1–2 weeks
Standard	500mcg	Once daily
Intranasal	250–500mcg	Once daily, divided across nostrils

Standard cycle: 4 weeks on, 4 weeks off.

Where to Go From Here

• The Cognitive Compound Group — Semax and Selank compared in full
• Semax: The Complete Guide
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.